<?xml version="1.0" encoding="utf-8" ?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>PR.com Press Releases: ParagonRx News</title>
		<link>https://www.PR.com/</link>
		<description>Latest news releases from PR.com for ParagonRx.</description>
		<lastBuildDate>Sun, 19 Apr 2026 12:17:55 -0400</lastBuildDate>
		<copyright>&#169; 2026 PR.com</copyright>
		<ttl>60</ttl>
		<language>en-us</language>
		<image>
			<url>https://www.PR.com/images/logo_white.jpg</url>
			<title>PR.com Press Releases: ParagonRx News</title>
			<link>https://www.PR.com/</link>
			<width>68</width>
			<height>69</height>
			<description>PR.com provides press release distribution, and is a unique directory of businesses, products and services. Find full company profiles.</description>
		</image>
		<atom:link href="https://www.pr.com/rss/press-releases-2/105112.xml" rel="self" type="application/rss+xml" />
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/184302</guid>
			<title>Risk Evaluation and Mitigation Strategy Experts Continue Interpreting New FDA REMS Guidance</title>
			<pubDate>Fri, 09 Oct 2009 03:00:00 -0400</pubDate>
			<description>Recently, the FDA issued a very important draft guidance for pharmaceutical and biotechnology companies for formatting, assessing and modifying Risk Evaluation Mitigation Strategies (REMS) to ensure the safe use of pharmaceutical products. Experts are now reviewing and interpreting this draft FDA guidance in  a series of blogs. [PR.com]</description>
			<link>https://www.pr.com/press-release/184302</link>
			<dc:creator>ParagonRx</dc:creator>
		</item>
	</channel>
</rss>